Red X iconGreen tick iconYellow tick icon

Murray Barclay (2018)Clinical Pharmacologist | Gastroenterologist

MD FRACP

Email murray.barclay@cdhb.health.nz

Professor Murray Barclay is a clinical pharmacologist, gastroenterologist, and clinical professor with the University of Otago, Christchurch. His research interests include inflammatory bowel disease genetics and pharmacogenetics, optimising medicines in gastroenterology and rheumatology, immune modulating drugs, and drug concentration monitoring.

He developed Interactive Clinical Pharmacology (www.icp.org.nz) with graphical web-based modules for teaching clinical pharmacology.

Publications

Stamp, L. K., Keating, P., Frampton, C., Barclay, M. L., Fanning, N., Millier, M., Hessian, P. A., & O'Donnell, J. L. (2024). Relationship between adalimumab concentrations, anti-drug antibodies and disease activity in rheumatoid arthritis: A cross-sectional observational study. Journal of Rheumatology. Advance online publication. doi: 10.3899/jrheum.2023-0706

Stamp, L. K., Horsley, C., Te Karu, L., Dalbeth, N., & Barclay, M. (2023). Colchicine: The good, the bad, the ugly, and how to minimise the risks. Rheumatology, kead625. Advance online publication. doi: 10.1093/rheumatology/kead625

Barclay, M. L., Keating, P. E., Hock, B. D., Chin, P. K. L., & O'Donnell, J. L. (2023). Infliximab or adalimumab antidrug-antibody complex size has more clinical value than concentration. Proceedings of the Australasian Society of Clinical & Experimental Pharmacologists & Toxicologists (ASCEPT) Annual Scientific Meeting: Transformational Pharmacology & Toxicology. 235. Retrieved from https://www.asceptasm.com

Barclay, M. L., Ovenden, C., Anderson, A., & Chou, E. (2023). Thioguanine efficacy, safety and TDM in IBD patients in New Zealand. Proceedings of the Australasian Society of Clinical & Experimental Pharmacologists & Toxicologists (ASCEPT) Annual Scientific Meeting: Transformational Pharmacology & Toxicology. P514. Retrieved from https://www.asceptasm.com

Barclay, M. L., Keating, P. E., Hock, B. D., Smith, S. M., Chin, P. K. L., & O'Donnell, J. L. (2023). Four-year review of New Zealand laboratory infliximab and adalimumab concentration results indicating high potential for improved dosing. Proceedings of the Australasian Society of Clinical & Experimental Pharmacologists & Toxicologists (ASCEPT) Annual Scientific Meeting: Transformational Pharmacology & Toxicology. P513. Retrieved from https://www.asceptasm.com

Back to top